Exelixis
Small-molecule kinase inhibitors and targeted cancer therapeutics
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Latest Form D
- $3M offered, Jul 2009
- Total capital
- $3.4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $3M
- 1 Form D · last Jul 2009
- 207 months since last filing
- Federal contracts
- $401K
- 39 awards · Veterans Affairs
- Rank in Biotech#240 of 4373
- Granted patents
- 15
- 25 pending · first 2024
- Rank in peer group#26 of 1449
Capital timeline
Latest events
- Federal contractVeterans Affairs · Comtriq 140MG$76K
- Federal contractVeterans Affairs · Cabozantinib$7K
- Federal contractVeterans Affairs · Cabozantinib (cometriq) 100 Mg Cap$7K
- Federal contractVeterans Affairs · Comtetriq 60MG Capsules$7K
- Federal contractVeterans Affairs · Cabozantitinb$14K
- Federal contractVeterans Affairs · Pharmacy - Cometriq Medicine$7K
- Federal contractVeterans Affairs · Cabozantinib 60 Mg Caps Cometriq$7K
- Offering registeredForm D · SEC · 1st filing$3M
Show 31 earlier federal awards
- Federal contractVeterans Affairs · Cometriq 60MG$7K
- Federal contractVeterans Affairs · Carbonzantinib$21K
- Federal contractVeterans Affairs · Medication Cometriq (cabozantinib) 140 Mg$14K
- Federal contractVeterans Affairs · Cometriq Drug 100 Mg Caps 28 Day Supply$7K
- Federal contractVeterans Affairs · Emergency Drug-cometriq$21K
- Federal contractVeterans Affairs · Cometriq (cabozantinib)$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq 140 Mg Capsules$7K
- Federal contractVeterans Affairs · Cometriq$5K
- Federal contractVeterans Affairs · Cometriq Drug 100MG Caps$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq$14K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq 100MG$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq (60MG)$14K
- Federal contractVeterans Affairs · Cabozanitinib$7K
- Federal contractVeterans Affairs · Cometriq$15K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq 100 Mg$7K
- Federal contractVeterans Affairs · Cometriq 60 Mg$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cometriq 60MG$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Cabozantinib 140MG Caps Cometriq.$7K
- Federal contractVeterans Affairs · Cometriq$7K
- Federal contractVeterans Affairs · Chemo Medication: Cabozantinib (cometriq) 140MG$7K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#26 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan M. GarberDirectorNamed in SEC Form D filings
- Carl B. FeldbaumDirectorNamed in SEC Form D filings
- Charles CohenDirectorNamed in SEC Form D filings
- Frances K. HellerExecutive OfficerNamed in SEC Form D filings
- Frank L. KarbeExecutive OfficerNamed in SEC Form D filings
- Frank McCormickDirectorNamed in SEC Form D filings
Show all 17 people
- George PosteDirectorNamed in SEC Form D filings
- George A. ScangosExecutive Officer, DirectorNamed in SEC Form D filings
- Gisela M. SchwabExecutive OfficerNamed in SEC Form D filings
- Jack L. WyszomierskiDirectorNamed in SEC Form D filings
- Lance WillseyDirectorNamed in SEC Form D filings
- Lupe M. RiveraExecutive OfficerNamed in SEC Form D filings
- Michael M. MorrisseyExecutive OfficerNamed in SEC Form D filings
- Pamela A. SimontonExecutive OfficerNamed in SEC Form D filings
- Peter LambExecutive OfficerNamed in SEC Form D filings
- Stelios PapadopoulosDirectorNamed in SEC Form D filings
- Vincent T. MarchesiDirectorNamed in SEC Form D filings
What it has protected
USPTO · 15 granted of 40- GrantedPD-L1 Binding Agents And Uses ThereofUSPTOUS 12,679,893
- GrantedCrystalline Forms And Salt Forms Of A Kinase InhibitorUSPTOUS 12,679,809
- PendingProcesses for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such CompoundsUSPTOApplication 19536844
Show all 40 patent records
- PD-L1 Binding Agents And Uses ThereofJul 14, 2026 · US 12,679,893Granted
- Crystalline Forms And Salt Forms Of A Kinase InhibitorJul 14, 2026 · US 12,679,809Granted
- Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such CompoundsJul 9, 2026 · Application 19536844Pending
- Combinations For The Treatment Of CancerJul 7, 2026 · US 12,673,052Granted
- Compounds that Inhibit PKMYT1Jun 25, 2026 · Application 19132531Pending
- 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORSJun 4, 2026 · Application 19122606Pending
- Somatostatin Receptor 2 Agonists And Uses ThereofFeb 26, 2026 · Application 19190582Pending
- Compounds for the Treatment of Kinase-Dependent DisordersDec 23, 2025 · US 12,503,438Granted
- Processes for the Preparation of a Kinase InhibitorDec 16, 2025 · US 12,497,367Granted
- C-Met Modulator Pharmaceutical CompositionsDec 4, 2025 · Application 19305080Pending
- Crystalline Forms And Salt Forms Of A Kinase InhibitorDec 4, 2025 · Application 18723013Pending
- Crystalline Solid Forms Of N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, Processes For Making, And Methods Of UseDec 2, 2025 · US 12,486,233Granted
- 5T4 Binding Agents And Uses ThereofOct 23, 2025 · Application 18863565Pending
- 5T4 Antibody-drug Conjugates And Uses ThereofSep 25, 2025 · Application 18863572Pending
- Processes For Preparing Quinoline Compounds And Pharmaceutical Compositions Containing Such CompoundsAug 21, 2025 · Application 19202778Pending
- Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerJul 31, 2025 · Application 19069917Pending
- Pyridone Compounds And Methods Of UseJul 29, 2025 · US 12,371,428Granted
- Multispecific Binding Agents And Uses ThereofJun 19, 2025 · Application 18836677Pending
- Fused Bicyclic Heterocyclyl Compounds As USP1 InhibitorsMay 22, 2025 · Application 18834799Pending
- C-met Modulator Pharmaceutical CompositionsMay 1, 2025 · Application 19007899Pending
- Malate Salt Of N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, And Crystalline Forms Thereof For The Treatment Of CancerApr 15, 2025 · US 12,275,706Granted
- Heterocyclic Adenosine Receptor AntagonistsApr 1, 2025 · US 12,264,161Granted
- Pharmaceutical Compositions Comprising Anti-tissue Factor Antibody-drug ConjugatesMar 27, 2025 · Application 18730679Pending
- Mek Inhibitors And Methods Of Their UseMar 27, 2025 · Application 18672226Pending
- Crystalline Solid Forms Of Salts Of N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, Processes For Making, And Methods Of UseFeb 18, 2025 · US 12,227,481Granted
- Compounds For The Treatment Of Kinase-dependent DisordersFeb 13, 2025 · Application 18706757Pending
- Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such CompoundsJan 16, 2025 · Application 18899774Pending
- Compounds for the Treatment of Kinase-Dependent DisordersJan 14, 2025 · US 12,195,475Granted
- Anti-ror Antibody ConstructsNov 28, 2024 · Application 18801013Pending
- Processes For Preparing Quinoline Compounds And Pharmaceutical Compositions Containing Such CompoundsOct 29, 2024 · US 12,128,039Granted
- Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioateOct 24, 2024 · Application 18359214Pending
- Method Of Treating Cancer And Bone Cancer PainSep 26, 2024 · Application 18733183Pending
- Liquid Dosage Forms to Treat CancerSep 19, 2024 · Application 18661030Pending
- Anti-ror Antibody ConstructsSep 10, 2024 · US 12,084,496Granted
- Metabolites Of N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDEAug 29, 2024 · Application 18641587Pending
- Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerAug 22, 2024 · Application 18612538Pending
- Liquid Dosage Forms to Treat CancerJun 25, 2024 · US 12,016,854Granted
- Crystalline Forms and Salt Forms of a Kinase InhibitorJun 25, 2024 · US 12,017,995Granted
- C-Met Modulator Pharmaceutical CompositionsMay 16, 2024 · Application 18491407Pending
- Pyridone Compounds And Methods Of UseMay 16, 2024 · Application 18277956Pending
Related companies, and why
- Rejuvenics Technologies LLCSimilar federal contract value in Biotech · $438K in contracts
- Litron Laboratories LtdSimilar federal contract value in Biotech · $426K in contracts
- Cell Surgical Network CorporationSimilar federal contract value in Biotech · $413K in contracts
- Stemgent, Inc.Similar federal contract value in Biotech · $400K in contracts
- RIPTIDE THERAPEUTICS LLCSimilar federal contract value in Biotech · $400K in contracts
- TRITERPENOID THERAPEUTICS INCSimilar federal contract value in Biotech · $400K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .